Patents by Inventor Rama ABU SHMEIS
Rama ABU SHMEIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404918Abstract: The present disclosure provides methods of treating breast cancer including administering aqueous suspensions com-prising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(1 0) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.Type: ApplicationFiled: February 14, 2023Publication date: December 21, 2023Inventors: Feng-Jing CHEN, Steven L. KRILL, Rama Abu SHMEIS, Adrian HEPNER, Charles WESCOTT, Tara JASKOWSKI, Michael JOYCE
-
Patent number: 11590077Abstract: The present disclosure provides methods of treating breast cancer including administering aqueous suspensions comprising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(10) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.Type: GrantFiled: November 8, 2018Date of Patent: February 28, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Feng-Jing Chen, Steven L. Krill, Rama Abu Shmeis, Adrian Hepner, Charles Wescott, Tara Jaskowski, Michael Joyce
-
Publication number: 20210346396Abstract: The disclosure is directed to fulvestrant formulations including suspensions of fulvestrant particles suitable for injection. The formulations can comprise fulvestrant particles having an LD Dv(10) less than about 3 microns, for example, between about 1 micron to about 3 microns, an LD Dv(50) less than about 35 microns, for example, between about 2 microns and about 35 microns, and an LD Dv(90) less than about 120 microns, for example, between about 4 microns and about 120 microns. The formulations can comprise fulvestrant particles having a CE Dv(90) less than about 200 microns, for example, between about 10 microns and about 200 microns, a CE Dv(50) less than about 60 microns, for example, between about 5 microns and about 60 microns, and a CE Dv(10) less than about 25 microns, for example, between about 1 microns and about 25 microns.Type: ApplicationFiled: July 19, 2021Publication date: November 11, 2021Inventors: Feng-Jing Chen, Steven L. Krill, Rama Abu Shmeis
-
Publication number: 20200360284Abstract: The present disclosure provides methods of treating breast cancer including administering aqueous suspensions comprising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(10) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.Type: ApplicationFiled: November 8, 2018Publication date: November 19, 2020Inventors: Feng-Jing CHEN, Steven L. KRILL, Rama Abu SHMEIS, Adrian HEPNER, Charles WESCOTT, Tara JASKOWSKI, Michael JOYCE
-
Patent number: 10751287Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: GrantFiled: March 12, 2014Date of Patent: August 25, 2020Assignee: Purdue Pharma L.P.Inventors: Rama Abu Shmeis, Sheetal Muley, Zhixin Zong
-
Patent number: 10517832Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: GrantFiled: December 28, 2018Date of Patent: December 31, 2019Assignee: Purdue Pharma L.P.Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Publication number: 20190167597Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: December 28, 2018Publication date: June 6, 2019Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Publication number: 20190134059Abstract: The disclosure is directed to fulvestrant formulations including suspensions of fulvestrant particles suitable for injection. The formulations can comprise fulvestrant particles having an LD Dv(10) less than about 3 microns, for example, between about 1 micron to about 3 microns, an LD Dv(50) less than about 35 microns, for example, between about 2 microns and about 35 microns, and an LD Dv(90) less than about 120 microns, for example, between about 4 microns and about 120 microns. The formulations can comprise fulvestrant particles having a CE Dv(90) less than about 200 microns, for example, between about 10 microns and about 200 microns, a CE Dv(50) less than about 60 microns, for example, between about 5 microns and about 60 microns, and a CE Dv(10) less than about 25 microns, for example, between about 1 micron and about 25 microns.Type: ApplicationFiled: May 5, 2017Publication date: May 9, 2019Inventors: Feng-Jing CHEN, Steven L. KRILL, Rama Abu SHMEIS
-
Patent number: 10195152Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: GrantFiled: April 11, 2017Date of Patent: February 5, 2019Assignee: PURDUE PHARMA L.P.Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Publication number: 20170216215Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: April 11, 2017Publication date: August 3, 2017Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Patent number: 9616030Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: GrantFiled: March 14, 2014Date of Patent: April 11, 2017Assignee: Purdue Pharma L.P.Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Publication number: 20160038427Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Inventors: Rama ABU SHMEIS, Sheetal R. MULEY, Xiaohong SHEN, Zhixin ZONG
-
Publication number: 20140341984Abstract: Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising a compressed core comprising: (i) an active agent susceptible to abuse and (ii) a gelling agent; wherein the plurality of particles contains a therapeutically or prophylactically effective amount of the active agent; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration.Type: ApplicationFiled: September 14, 2012Publication date: November 20, 2014Inventors: Rama Abu Shmeis, Sheetal R. Muley, William McKenna
-
Publication number: 20140271896Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Purdue Pharma L.P.Inventors: Rama ABU SHMEIS, Sheetal Muley, Zhixin Zong
-
Publication number: 20060269608Abstract: The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.Type: ApplicationFiled: February 2, 2004Publication date: November 30, 2006Inventors: Rama Abu Shmeis-Ziadeh, James Kowalski, Steven Krill, Lakshman Parthiban, Zeren Wang